$CATX
Perspective Therapeutics Inc Stock $catx

$catx Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000143774923014658 Filed on May 15, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q4
Revenue	$2.088M	$2.063M	$1.840M
YoY Change	-16.65%	-29.11%	-34.66%
Cost Of Revenue	$1.840M	$1.576M	$1.430M
YoY Change	16.53%	7.28%	-10.4%
Gross Profit	$248.0K	$487.0K	$400.0K
YoY Change	-73.22%	-66.2%	-67.21%
Gross Profit Margin	11.88%	23.61%	21.74%
Selling, General & Admin	$5.984M	$7.835M	$3.190M
YoY Change	167.62%	245.46%	37.5%
% of Gross Profit	2412.9%	1608.83%	797.5%
Research & Development	$5.653M	$3.857M	$590.0K
YoY Change	610.18%	602.55%	10.28%
% of Gross Profit	2279.44%	791.99%	147.5%
Depreciation & Amortization	$260.0K	$180.0K	$80.00K
YoY Change	246.67%	143.24%	12.68%
% of Gross Profit	104.84%	36.96%	20.0%
Operating Expenses	$11.62M	$11.71M	$3.780M
YoY Change	283.31%	315.83%	32.4%
Operating Profit	-$11.37M	-$11.23M	-$3.380M
YoY Change	440.08%	715.92%	106.73%
Interest Expense	$28.00K	$18.00K	$420.0K
YoY Change	0.0%	-37.93%	1254.84%
% of Operating Profit
Other Income/Expense, Net	$268.0K	$356.0K
YoY Change	857.14%	1127.59%
Pretax Income	-$11.11M	-$10.87M	-$3.270M
YoY Change	434.46%	707.05%	103.87%
Income Tax	$0.00	-$10.50M
% Of Pretax Income
Net Earnings	-$11.11M	-$371.0K	-$3.270M
YoY Change	434.46%	-72.46%	103.87%
Net Earnings / Revenue	-531.9%	-17.98%	-177.72%
Basic Earnings Per Share	-$0.04	$0.00
Diluted Earnings Per Share	-$0.04	$0.00	-$0.02
COMMON SHARES
Basic Shares Outstanding	280.1M	228.6M	142.1M
Diluted Shares Outstanding	28.00M	228.6M

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$28.30M	$36.50M	$43.80M
YoY Change	-49.36%	-38.03%	-27.43%
Cash & Equivalents	$28.32M	$36.45M	$20.99M
Short-Term Investments		$0.00	$22.80M
Other Short-Term Assets	$1.400M	$1.000M	$600.0K
YoY Change	5085.19%	81.49%	12.15%
Inventory	$1.094M	$1.408M	$1.409M
Prepaid Expenses
Receivables	$1.113M	$1.400M	$1.363M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$31.95M	$40.27M	$53.22M
YoY Change	-46.14%	-35.84%	-16.33%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.043M	$6.733M	$1.684M
YoY Change	256.43%	247.96%	-14.65%
Goodwill	$27.32M	$27.32M	$0.00
YoY Change
Intangibles	$50.00M	$50.00M	$0.00
YoY Change
Long-Term Investments			$150.0K
YoY Change
Other Assets	$573.0K	$567.0K	$236.0K
YoY Change	435.51%	472.73%	114.55%
Total Long-Term Assets	$88.19M	$87.38M	$4.876M
YoY Change	1625.85%	2504.44%	33.66%
TOTAL ASSETS
Total Short-Term Assets	$31.95M	$40.27M	$53.22M
Total Long-Term Assets	$88.19M	$87.38M	$4.876M
Total Assets	$120.1M	$127.6M	$58.09M
YoY Change	86.45%	93.07%	-13.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.900M	$3.900M	$1.500M
YoY Change	407.25%	407.15%	77.1%
Accrued Expenses	$3.600M	$3.200M	$1.100M
YoY Change	176.92%	169.59%	10.22%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$100.0K	$100.0K
YoY Change
Total Short-Term Liabilities	$8.589M	$7.194M	$2.676M
YoY Change	279.04%	267.79%	45.04%
LONG-TERM LIABILITIES
Long-Term Debt	$1.700M	$1.700M	$0.00
YoY Change
Other Long-Term Liabilities	$1.200M	$700.0K	$800.0K
YoY Change	33.93%	-26.78%	-21.26%
Total Long-Term Liabilities	$2.900M	$2.400M	$800.0K
YoY Change	223.66%	151.05%	-21.26%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.589M	$7.194M	$2.676M
Total Long-Term Liabilities	$2.900M	$2.400M	$800.0K
Total Liabilities	$11.49M	$9.617M	$3.449M
YoY Change	263.44%	230.25%	20.55%
SHAREHOLDERS EQUITY
Retained Earnings	-$117.4M	-$106.3M	-$105.9M
YoY Change	19.08%	10.14%	11.31%
Common Stock	$226.1M	$224.3M	$160.6M
YoY Change	41.4%	40.45%	0.63%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$108.7M	$118.0M	$54.64M
YoY Change
Total Liabilities & Shareholders Equity	$120.1M	$127.6M	$58.09M
YoY Change	86.45%	93.07%	-13.62%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q4
OPERATING ACTIVITIES
Net Income	-$11.11M	-$371.0K	-$3.270M
YoY Change	434.46%	-72.46%	103.87%
Depreciation, Depletion And Amortization	$260.0K	$180.0K	$80.00K
YoY Change	246.67%	143.24%	12.68%
Cash From Operating Activities	-$8.080M	-$9.723M	-$4.330M
YoY Change	179.49%	583.76%	229.78%
INVESTING ACTIVITIES
Capital Expenditures	$570.0K	$201.0K	$60.00K
YoY Change	-563.41%	-873.08%	-174.07%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$25.46M	$6.390M
YoY Change
Cash From Investing Activities	-$570.0K	$25.26M	$6.330M
YoY Change	363.41%	-97261.54%	-7914.81%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	510.0K	-$80.00K	0.000
YoY Change			-100.0%
NET CHANGE
Cash From Operating Activities	-8.080M	-$9.723M	-4.330M
Cash From Investing Activities	-570.0K	$25.26M	6.330M
Cash From Financing Activities	510.0K	-$80.00K	0.000
Net Change In Cash	-8.140M	$15.46M	2.000M
YoY Change	170.07%	-1167.61%	-249.48%
FREE CASH FLOW
Cash From Operating Activities	-$8.080M	-$9.723M	-$4.330M
Capital Expenditures	$570.0K	$201.0K	$60.00K
Free Cash Flow	-$8.650M	-$9.924M	-$4.390M
YoY Change	212.5%	610.89%	256.33%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	7000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	7000000
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	278657841
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	278657841
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	142112766
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	142112766
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-33407
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	41-1458152
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	350 Hills St., Suite 106
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Richland
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	WA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	99354
CY2023Q1	dei	City Area Code CityAreaCode	509
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	375-1202
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
CY2023Q1	dei	Trading Symbol TradingSymbol	CATX
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NYSEAMER
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	280131359
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36452000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20993000	usd
CY2023Q1	us-gaap	Short Term Investments ShortTermInvestments	0	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	22764000	usd
CY2023Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	1364000	usd
CY2022Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	1363000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	1408000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	1409000	usd
CY2023Q1	us-gaap	Notes Receivable Net NotesReceivableNet	0	usd
CY2022Q4	us-gaap	Notes Receivable Net NotesReceivableNet	6109000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1042000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	577000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	40266000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	53215000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6733000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1684000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	309000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	378000	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	182000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	182000	usd
CY2023Q1	us-gaap	Inventory Noncurrent InventoryNoncurrent	2269000	usd
CY2022Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	2396000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	50000000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	0	usd
CY2023Q1	us-gaap	Goodwill Goodwill	27319000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	0	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	567000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	236000	usd
CY2023Q1	us-gaap	Assets Assets	127645000	usd
CY2022Q4	us-gaap	Assets Assets	58091000	usd
CY2023Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3914000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1541000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	280000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	276000	usd
CY2023Q1	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	354000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	233000	usd
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	15000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	129000	usd
CY2023Q1	catx	Accrued Payroll And Related Taxes Current AccruedPayrollAndRelatedTaxesCurrent	1787000	usd
CY2022Q4	catx	Accrued Payroll And Related Taxes Current AccruedPayrollAndRelatedTaxesCurrent	212000	usd
CY2023Q1	us-gaap	Accrued Vacation Current AccruedVacationCurrent	764000	usd
CY2022Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	285000	usd
CY2023Q1	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	80000	usd
CY2022Q4	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	0	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	7194000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2676000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	44000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	116000	usd
CY2023Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	1713000	usd
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	0	usd
CY2023Q1	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	666000	usd
CY2022Q4	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	657000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	9617000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	3449000	usd
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	279000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	142000	usd
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	224052000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	160432000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-106303000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-105932000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	118028000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	54642000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	127645000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	58091000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1830000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2910000	usd
CY2023Q1	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	233000	usd
CY2022Q1	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	0	usd
CY2023Q1	us-gaap	Revenues Revenues	2063000	usd
CY2022Q1	us-gaap	Revenues Revenues	2910000	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1576000	usd
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1469000	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	487000	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	1441000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3857000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	549000	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	812000	usd
CY2022Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	687000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7023000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1581000	usd
CY2023Q1	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-22000	usd
CY2022Q1	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-0	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	11714000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	2817000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-11227000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1376000	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	374000	usd
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	29000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	18000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	-0	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	356000	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	29000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10871000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1347000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-10500000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-371000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-1347000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	228591000
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	142040000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-371000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-1347000	usd
CY2023Q1	catx	Noncash Expense Lease NoncashExpenseLease	1000	usd
CY2022Q1	catx	Noncash Expense Lease NoncashExpenseLease	0	usd
CY2023Q1	us-gaap	Depreciation Depreciation	180000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	64000	usd
CY2023Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-22000	usd
CY2022Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-0	usd
CY2023Q1	us-gaap	Adjustment For Amortization AdjustmentForAmortization	10000	usd
CY2022Q1	us-gaap	Adjustment For Amortization AdjustmentForAmortization	10000	usd
CY2023Q1	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	9000	usd
CY2022Q1	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	8000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1368000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	157000	usd
CY2023Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-10500000	usd
CY2022Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	493000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-128000	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-84000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	60000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	16000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-595000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-76000	usd
CY2023Q1	catx	Increase Decrease In Accrued Protocol Expense IncreaseDecreaseInAccruedProtocolExpense	121000	usd
CY2022Q1	catx	Increase Decrease In Accrued Protocol Expense IncreaseDecreaseInAccruedProtocolExpense	-28000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-114000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-9000	usd
CY2023Q1	catx	Increase Decrease In Accrued Payroll And Related Taxes IncreaseDecreaseInAccruedPayrollAndRelatedTaxes	-67000	usd
CY2022Q1	catx	Increase Decrease In Accrued Payroll And Related Taxes IncreaseDecreaseInAccruedPayrollAndRelatedTaxes	225000	usd
CY2023Q1	catx	Increase Decrease In Accrued Vacation IncreaseDecreaseInAccruedVacation	146000	usd
CY2022Q1	catx	Increase Decrease In Accrued Vacation IncreaseDecreaseInAccruedVacation	-3000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9723000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1424000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	201000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	26000	usd
CY2023Q1	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	22764000	usd
CY2022Q1	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	0	usd
CY2023Q1	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	2699000	usd
CY2022Q1	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	25262000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-26000	usd
CY2023Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	15000	usd
CY2022Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	-0	usd
CY2023Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	65000	usd
CY2022Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	-0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-80000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	15459000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1450000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	21175000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	60536000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	36634000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	59086000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36452000	usd
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	58904000	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	182000	usd
CY2022Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	182000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	36634000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	59086000	usd
CY2023Q1	catx	Noncash Or Part Noncash Acquisition Value Of Assets Acquired Including Goodwill NoncashOrPartNoncashAcquisitionValueOfAssetsAcquiredIncludingGoodwill	85885000	usd
CY2022Q1	catx	Noncash Or Part Noncash Acquisition Value Of Assets Acquired Including Goodwill NoncashOrPartNoncashAcquisitionValueOfAssetsAcquiredIncludingGoodwill	0	usd
CY2023Q1	us-gaap	Stock Issued1 StockIssued1	54618000	usd
CY2022Q1	us-gaap	Stock Issued1 StockIssued1	-0	usd
CY2023Q1	catx	Noncash Or Part Noncash Acquisition Assumption Of Stock Options And Warrants NoncashOrPartNoncashAcquisitionAssumptionOfStockOptionsAndWarrants	-7836000	usd
CY2022Q1	catx	Noncash Or Part Noncash Acquisition Assumption Of Stock Options And Warrants NoncashOrPartNoncashAcquisitionAssumptionOfStockOptionsAndWarrants	0	usd
CY2023Q1	catx	Noncash Or Part Noncash Acquisition Notes Receivable And Accrued Interest Forgiven NoncashOrPartNoncashAcquisitionNotesReceivableAndAccruedInterestForgiven	-6171000	usd
CY2022Q1	catx	Noncash Or Part Noncash Acquisition Notes Receivable And Accrued Interest Forgiven NoncashOrPartNoncashAcquisitionNotesReceivableAndAccruedInterestForgiven	0	usd
CY2023Q1	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	17260000	usd
CY2022Q1	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	0	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	64391000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	157000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-1347000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	63201000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	54642000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	54553000	usd
CY2023Q1	catx	Adjustments To Additional Paid In Capital Assumption Of Stock Options And Warrants At Fair Value AdjustmentsToAdditionalPaidInCapitalAssumptionOfStockOptionsAndWarrantsAtFairValue	7836000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1368000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-371000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	118028000	usd
CY2023Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2023Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	pure
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><span style="text-decoration: underline; ">Use of Estimates</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The preparation of condensed consolidated financial statements in accordance with GAAP requires management of the Company to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes of the Company including the fair value of net assets acquired in a business combination; the allowance for doubtful accounts receivable; net realizable value of the enriched barium inventory; the estimated useful lives used in calculating depreciation and amortization on the Company’s fixed assets, patents, trademarks, intangible assets and other assets; estimated amount and fair value of the asset retirement obligation related to the Company’s production facilities; equity method investment; and inputs to the Black-Scholes calculation used in determining the expense related to share-based compensation including volatility and estimated lives of options granted and impairment of long-lived assets including intangible assets and goodwill. Accordingly, actual results could differ from those estimates and affect the amounts reported in the financial statements.</p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;"/>
CY2023Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	pure
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	43903000
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9572000
CY2023Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	777000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	752000	usd
CY2023Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	616000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	636000	usd
CY2023Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	15000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	21000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	1408000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	1409000	usd
CY2023Q1	us-gaap	Inventory Noncurrent InventoryNoncurrent	2269000	usd
CY2022Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	2396000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	14544000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9315000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7811000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7631000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6733000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1684000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	27300000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	0	usd
CY2022Q4	us-gaap	Goodwill Goodwill	0	usd
CY2023Q1	us-gaap	Goodwill Goodwill	27319000	usd
CY2023Q1	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	50000000	usd
CY2023Q1	catx	Indefinitelived Intangible Assets Accumulated Amortization IndefinitelivedIntangibleAssetsAccumulatedAmortization	0	usd
CY2023Q1	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	50000000	usd
CY2022Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	0	usd
CY2022Q4	catx	Indefinitelived Intangible Assets Accumulated Amortization IndefinitelivedIntangibleAssetsAccumulatedAmortization	0	usd
CY2022Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	0	usd
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y6M10D
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1368000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	157000	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	798432	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y3M7D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10806200
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.56
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y11M4D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2800000
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.38
CY2023Q1	catx	Sharebased Compensation Arrangement By Sharebased Payment Award Options Assumed In Period Gross SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAssumedInPeriodGross	24263424
CY2023Q1	catx	Sharebased Compensation Arrangements By Sharebased Payment Award Options Assumed In Period Weighted Average Exercise Price SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsAssumedInPeriodWeightedAverageExercisePrice	0.17
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	37869624
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.30
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y8M12D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	12989000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	35121848
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.29
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	12330000	usd
CY2022Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2800000
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
CY2023Q1	catx	Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants In Period Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue	849000	usd
CY2022Q1	catx	Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants In Period Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue	0	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	0
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	113575
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	413700
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.30
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	2800000
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	114000	usd
CY2022Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	78000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	219000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	118000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	337000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	13000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	324000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	280000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	44000	usd
CY2023Q1	us-gaap	Notes Payable NotesPayable	1793000	usd
CY2022Q4	us-gaap	Notes Payable NotesPayable	0	usd
CY2023Q1	us-gaap	Notes Payable Current NotesPayableCurrent	80000	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	-0	usd
CY2023Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	1713000	usd
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	0	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	68000	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	49000	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	52000	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	55000	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	1569000	usd
CY2023Q1	us-gaap	Long Term Debt LongTermDebt	1793000	usd
CY2023Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	pure
CY2023Q1	us-gaap	Revenues Revenues	2063000	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	487000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-11227000	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	374000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	18000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	190000	usd
CY2022Q1	us-gaap	Revenues Revenues	2910000	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	1441000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1376000	usd
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	29000	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	74000	usd
CY2023Q1	us-gaap	Financing Receivable Allowance For Credit Losses Write Offs FinancingReceivableAllowanceForCreditLossesWriteOffs	6170000	usd
CY2023Q1	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	2063000	usd
CY2022Q1	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	3128000	usd
CY2023Q1	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-6259000	usd
CY2022Q1	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	1597000	usd

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001437749-23-014658-index-headers.html	Edgar Link	pending
0001437749-23-014658-index.html	Edgar Link	pending
0001437749-23-014658.txt	Edgar Link	pending
0001437749-23-014658-xbrl.zip	Edgar Link	pending
b01.jpg	Edgar Link	pending
b02.jpg	Edgar Link	pending
b03.jpg	Edgar Link	pending
b04.jpg	Edgar Link	pending
catx-20230331.xsd	Edgar Link	pending
ex_502170.htm	Edgar Link	pending
ex_502171.htm	Edgar Link	pending
ex_502172.htm	Edgar Link	pending
ex_502173.htm	Edgar Link	pending
ex_520386.htm	Edgar Link	pending
ex_520387.htm	Edgar Link	pending
ex_520388.htm	Edgar Link	pending
ex_520389.htm	Edgar Link	pending
ex_520390.htm	Edgar Link	pending
ex_520391.htm	Edgar Link	pending
ex_520697.htm	Edgar Link	pending
catx-20230331_pre.xml	Edgar Link	unprocessable
catx-20230331_lab.xml	Edgar Link	unprocessable
catx-20230331_def.xml	Edgar Link	unprocessable
catx-20230331_cal.xml	Edgar Link	unprocessable
ex_520698.htm	Edgar Link	pending
ex_520700.htm	Edgar Link	pending
ex_520740.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
isr20230331_10q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
isr20230331_10q_htm.xml	Edgar Link	completed
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CATX
Perspective Therapeutics Inc Stock $catx

2023 Q2 Form 10-Q Financial Statement

#000143774923014658 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CATX Perspective Therapeutics Inc Stock $catx

2023 Q2 Form 10-Q Financial Statement

#000143774923014658 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CATX
Perspective Therapeutics Inc Stock $catx